Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
acute, admission, Alimta, answer, arose, arrangement, ASC, ASCO, ASU, Attorney, AUD, Australian, backlog, bacterial, basket, begun, biennial, Brabant, BRCA, causation, Cavatak, centralized, channel, Chinese, cisplatin, civil, clawback, coexistence, colistimethate, Colistin, comparison, Conference, confirmatory, conjugate, context, Counsel, coupon, criminal, criteria, customary, cyclase, Daubert, Dec, Decree, Department, depict, disproportionate, DMC, Dutch, Ebola, Eisai, enablement, enacted, enactment, endometrial, England, entitled, entrance, epidermal, epithelial, EUAL, expedient, factor, fallopian, fine, foregoing, geographic, GILTI, guanylate, healthy, heart, hospital, imipenem, immunogenicity, immunology, injunction, inspected, Inspector, intermediate, interpretation, intratumoral, investee, invited, invoice, invoiced, Ireland, Journal, Jurisdiction, Justice, Kabi, kidney, Labour, lack, Lancet, legislation, legislatively, lenvatinib, Lenvima, Levitra, mandated, Maryland, Maxalt, mentioned, merger, mesylate, Ministry, multinational, mutation, Mylan, nephrotoxicity, NewLink, NJ, oncolytic, Opportunistic, Organization, outbreak, paclitaxel, payback, peritoneal, PFS, platinum, PMBCL, Pneumococci, population, Portugal, preferential, preferentially, PRIME, prioritization, promise, proprietary, Prosecutor, Province, provisional, publicly, published, question, radically, rare, ratably, recast, referenced, releasing, relebactam, remitted, renewing, rental, residual, rest, restated, satisfied, scale, seasoned, SEC, secondary, sequentially, sGC, shelf, shipment, simultaneously, Singapore, Solicitor, soluble, Spain, sponsored, stranded, strong, substance, suspected, TCJA, technical, thromboembolic, tolerability, toxicity, tube, turn, tyrosine, unaffected, unbudgeted, undistributed, unsettled, usage, Variation, vast, vericiguat, virology, Welfare, worsening
Removed:
achieved, Agency, ALK, Allergan, allergic, allergy, antibiotic, antibody, asthma, bacteremia, bill, BMS, Bravecto, brentuximab, broadly, cancellation, cardiac, chloride, claimed, closing, Colaw, communication, complicated, composition, coordinate, corticosteroid, Corticotropin, Cortrophin, Cubicin, daptomycin, delay, deprioritized, dihydrate, direct, discussing, domestic, earned, EC, EGFR, element, ertugliflozin, ESI, etonogestrel, examination, floating, formalized, furoate, genomic, genotype, glycemic, greater, GT, Hospira, Hydroxide, IDO, implant, impracticable, increased, incremental, incur, indirect, ineligible, infarction, inhaled, innovative, IOmet, Lederle, letter, Lifetec, lose, lowered, manufacturer, metabolism, metformin, mometasone, monohydrate, montelukast, myeloma, myocardial, nasal, occurring, offering, Ono, people, peripheral, Pfizer, Pharma, potassium, preclinical, prescribing, presiding, proceed, prohibited, proportion, prospectively, PSC, putative, receiving, recommend, rehearing, reinvested, relationship, repatriated, reviewing, ribavirin, Savior, score, skin, SPMSD, Squibb, Steering, stem, stream, subdermal, supplement, susceptible, swine, system, TDO, terminate, terminated, testing, Teva, Thierry, thrombotic, trade, transplant, tumor, unconditionally, unremitted, vedotin, voted, XR, Zerbaxa, Zinc, Zontivity
Filing tables
Filing exhibits
- 10-Q Quarterly report
- 10 Exhibit 10: Psu Award Terms Under Merck & Co Inc 2010 Sip
- 31.1 Exhibit 31.1: Rule 13A-14(A)/15D-14(A) Certification of CEO
- 31.2 Exhibit 31.2: Rule 13A-14(A)/15D-14(A) Certification of CFO
- 32.1 Exhibit 32.1: Section 1350 Certification of CEO
- 32.2 Exhibit 32.2: Section 1350 Certification of CFO
- Download Excel data file
- View Excel data file
Related press release
Associated MRK transcripts
MRK similar filings
Filing view
External links
Exhibit 32.2
Section 1350
Certification of Chief Financial Officer
Pursuant to 18 U.S.C. Section 1350, the undersigned officer of Merck & Co., Inc. (the “Company”), hereby certifies that the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2018 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Dated: May 8, 2018 | /s/ Robert M. Davis | |
Name: Title: | ROBERT M. DAVIS Executive Vice President, Chief Financial Officer & Global Services |